Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested that treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients with idiopathic pulmonary fibrosis. METHODS: We conducted two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) to evaluate the efficacy and safety of 150 mg of nintedanib twice daily as compared with placebo in patients with idiopathic pulmonary fibrosis. The primary end point was the annual rate of decline in forced vital capacity (FVC). Key secondary end points were the time to the first acute exacerbation and the change from baseline in the total score on the St. George's Respiratory Questionnaire, both assessed over a 52-week period. RESULTS: A total of 1066 patients were randomly assigned in a 3:2 ratio to receive nintedanib or placebo. The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1 and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2. In INPULSIS-1, there was no significant difference between the nintedanib and placebo groups in the time to the first acute exacerbation (hazard ratio with nintedanib, 1.15; 95% CI, 0.54 to 2.42; P=0.67); in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P=0.005). The most frequent adverse event in the nintedanib groups was diarrhea, with rates of 61.5% and 18.6% in the nintedanib and placebo groups, respectively, in INPULSIS-1 and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2. CONCLUSIONS: In patients with idiopathic pulmonary fibrosis, nintedanib reduced the decline in FVC, which is consistent with a slowing of disease progression; nintedanib was frequently associated with diarrhea, which led to discontinuation of the study medication in less than 5% of patients. (Funded by Boehringer Ingelheim; INPULSIS-1 and INPULSIS-2 ClinicalTrials.gov numbers, NCT01335464 and NCT01335477.).
Overview
CoChat Summary
TL;DR
This paper reports two replicate 52-week phase 3 randomized trials showing that nintedanib slowed the decline in forced vital capacity in idiopathic pulmonary fibrosis. Diarrhea was common, but discontinuation due to study medication occurred in less than 5% of patients.
Key findings
- In INPULSIS-1, the adjusted annual rate of change in FVC was -114.7 ml with nintedanib vs -239.9 ml with placebo; the between-group difference was 125.3 ml (95% CI, 77.7 to 172.8; P<0.001).
- In INPULSIS-2, the adjusted annual rate of change in FVC was -113.6 ml with nintedanib vs -207.3 ml with placebo; the between-group difference was 93.7 ml (95% CI, 44.8 to 142.7; P<0.001).
- For time to first acute exacerbation, INPULSIS-1 showed no significant difference (HR 1.15, 95% CI, 0.54 to 2.42; P = 0.67), while INPULSIS-2 showed benefit with nintedanib (HR 0.38, 95% CI, 0.19 to 0.77; P = 0.005).
- The most frequent adverse event was diarrhea: 61.5% vs 18.6% in INPULSIS-1 and 63.2% vs 18.3% in INPULSIS-2 for nintedanib vs placebo, respectively; the conclusion states this led to discontinuation in less than 5% of patients.
Methods
- Two replicate 52-week, randomized, double-blind, phase 3 trials (INPULSIS-1 and INPULSIS-2) compared nintedanib 150 mg twice daily with placebo in patients with idiopathic pulmonary fibrosis.
- 1066 patients were randomly assigned in a 3:2 ratio to nintedanib or placebo.
- Primary outcome was the annual rate of decline in forced vital capacity (FVC); key secondary outcomes were time to first acute exacerbation and change in St. George’s Respiratory Questionnaire total score over 52 weeks.
Limitations
- The text does not state formal study limitations.
- Evident from the paper’s own reporting: the effect on acute exacerbation was inconsistent across the two replicate trials (no significant difference in INPULSIS-1, significant benefit in INPULSIS-2).
- Evident from the text: the provided excerpt does not report the full results for the St. George’s Respiratory Questionnaire outcome, so that secondary endpoint cannot be fully summarized from this text alone.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 1 Not valid · 0 Not checked · 11 Own results and interpretations
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“which led to discontinuation of the study medication in less than 5% of patients.”
states a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: unclear — It is unclear why the paper says it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“in INPULSIS-2, there was a significant benefit with nintedanib versus placebo (hazard ratio, 0.38; 95% CI, 0.19 to 0.77; P = 0.005).”
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and -113.6 ml with nintedanib versus -207.3 ml with placebo (difference, 93.7 ml; 95% CI, 44.8 to 142.7; P<0.001) in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and 63.2% and 18.3% in the two groups, respectively, in INPULSIS-2.”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The adjusted annual rate of change in FVC was -114.7 ml with nintedanib versus -239.9 ml with placebo (difference, 125.3 ml; 95% confidence interval [CI], 77.7 to 172.8; P<0.001) in INPULSIS-1”
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
5 more claims
Create a free account to see all 12 claims and every source verdict.
- It may state two separate claims as one. 1
- Probably not a substantial claim. 1
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Idiopathic pulmonary fibrosis (IPF), the prototype of fibrotic ILDs, carries a prognosis of 3–5 years survival after diagnosis when untreated. Two anti-fibrotic medications (nintedanib and pirfenidone) have been shown to reduce the rate of forced vital capacity (FVC) decline and slow disease progression in patients with a definite usual interstitial pneumonia (UIP) pattern and with a probable UIP pattern on high resolution CT (HRCT).(191–193)”
From Consensus document for the selection of lung transplant candidates: An update from the International Society for Heart and Lung Transplantation. (2021) · cites this paper as [192]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, both have significant adverse effects and neither completely arrest the decline in lung function.”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Reported adverse events in the present trial were generally acceptable and largely consistent with events previously reported by participants in the placebo arms of randomized controlled trials in IPF [45,46].”
From Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study (2019) · cites this paper as [46]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“nintedanib, which was originally developed with oncology in mind, for treatment of idiopathic pulmonary fibrosis150.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [150]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical trials investigating these two drugs in patients with IPF have demonstrated only a slowing of disease progression33,34, as measured by forced vital capacity (FVC) and self-reported quality of life (QOL) metrics, and unclear benefit to survival26, making the development of therapies that can restore lung function and reverse the course of disease a priority.”
From A generative AI-discovered TNIK inhibitor for idiopathic pulmonary fibrosis: a randomized phase 2a trial (2025) · cites this paper as [34]
Experimental — accuracy not yet measured
8 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Miller, M. R., Hankinson, J., Brusasco, V., Burgos, F., Casaburi, R., Coates, A., Crapo, R., Enright, P., van der Grinten, C. P. M., Gustafsson, P., et al. (2005) · European Respiratory Journal · doi:10.1183/09031936.05.00034805 · Cited by 15,627
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationThe St George's Respiratory Questionnaire
Jones, P. W., Quirk, F. H., & Baveystock, C. M. (1991) · Respiratory Medicine · doi:10.1016/s0954-6111(06)80166-6 · Cited by 2,683
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationEfficacy of a Tyrosine Kinase Inhibitor in Idiopathic Pulmonary Fibrosis
Richeldi, L., Costabel, U., Selman, M., Kim, D. S., Hansell, D. M., Nicholson, A. G., Brown, K. K., Flaherty, K. R., Noble, P. W., Raghu, G., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103690 · Cited by 1,157
Self-citationAcute Exacerbations of Idiopathic Pulmonary Fibrosis
Collard, H. R., Moore, B. B., Flaherty, K. R., Brown, K. K., Kaner, R. J., King, T. E., Lasky, J. A., Loyd, J. E., Noth, I., Olman, M. A., et al. (2007) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200703-463pp · Cited by 1,130
Self-citationBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056
St. George's Respiratory Questionnaire: MCID
Jones, P. W. (2005) · COPD: Journal of Chronic Obstructive Pulmonary Disease · doi:10.1081/copd-200050513 · Cited by 855
Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome
Song, J. W., Hong, S.-B., Lim, C.-M., Koh, Y., & Kim, D. S. (2011) · European Respiratory Journal · doi:10.1183/09031936.00159709 · Cited by 783
Self-citationChanges in Clinical and Physiologic Variables Predict Survival in Idiopathic Pulmonary Fibrosis
Collard, H. R., King, T. E., Bartelson, B. B., Vourlekis, J. S., Schwarz, M. I., & Brown, K. K. (2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200211-1311oc · Cited by 764
Self-citation
Cited by
Items 4,001–4,100 of 4,628
Weiterentwicklung in der Therapie rheumatischer Erkrankungen bei Kindern und Jugendlichen
Föll, D., & Kallinich, T. (2022) · Springer Reference Medizin · doi:10.1007/978-3-662-60410-6_24
Formulated Herbal Medicines for Idiopathic Pulmonary Fibrosis: A Case SeriesPreprint
Chan, M.-Y., Man, S., Qin, Z., Ho, C.-M. J., Yan, S.-W., Yee, K.-S., Kwok, H.-C., Zhang, L.-B., Shen, S. Y., Chen, Y., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4103300
Novel PDE4B inhibitor offers breakthrough for IPF
Richeldi, L., & Giles, R. (2022) · doi:10.55788/ec3f9465
Self-citationErol, A. Y. G., & Dirol, H. (2022) · Research Square · doi:10.21203/rs.3.rs-1897590/v1
Impact of Reduction in Antifibrotic Treatment on Mortality in Idiopathic Pulmonary FibrosisPreprint
Porse, S., Hoyer, N., & Shaker, S. B. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4184350
Association Between Weight Loss and Mortality in Idiopathic Pulmonary FibrosisPreprint
Kalininskiy, A., Rackow, A. R., Nagel, D. J., et al. (2022) · Research Square · doi:10.21203/rs.3.rs-1936563/v1
Witt, L. J., & Austin, C. A. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108942751.022
Perioperative Oxygen Concentration for Patients with Interstitial Pneumonia
Chiba, H. (2022) · THE JOURNAL OF JAPAN SOCIETY FOR CLINICAL ANESTHESIA · doi:10.2199/jjsca.42.396
Durán, A. C., Oriol, A. J., & Bobillo, J. R. (2022) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2022.09.012
Indicaciones de trasplante pulmonar
Durán, D., Franquiz, W. B., Bobillo, J. R., & Oriol, A. J. (2022) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2022.09.013
Einsatz antifibrotischer Medikamente bei interstitiellen Lungenerkrankungen
Kreutz, C.-P., Gesierich, W., Behr, J., & Kneidinger, N. (2022) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-1825-4967
Encouraging results of nintedanib in children with fibrosing ILD
van den Heivel, R. (2022) · doi:10.55788/2d89dada
Singh, H., Jankharia, B. G., Singh, S., Dhar, R., Gothi, D., Behera, D., Hadda, V., Talwar, D., Pilania, K., Desai, U. D., et al. (2022) · The Indian Journal of Chest Diseases and Allied Sciences · doi:10.5005/ijcdas-62-2-73
Bobillo, J. R., & Oriol, A. J. (2022) · Medicine - Programa de Formación Médica Continuada Acreditado · doi:10.1016/j.med.2022.11.018
WITHDRAWN: MRONJ Mimicking post COVID-19 mucormycosis; A diagnostic dilemma
Kudva, A., Saha, M., Gadicherla, S., & Shah, A. (2022) · Advances in Oral and Maxillofacial Surgery · doi:10.1016/j.adoms.2022.100383
RetractedFibroses pulmonaires : mise à jour des recommandations et nouveaux traitements
Bouvry, D. (2022) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(22)00775-3
Pulmonary Fibrosis: One Manifestation, Various Diseases
Ruaro, B., Matucci‐Cerinic, M., Baratella, E., Confalonieri, M., Salton, F., & Hughes, M. (2022) · Frontiers research topics · doi:10.3389/978-2-83250-654-7
Seguimiento de 20 pacientes portadores de fibrosis pulmonar idiopática tratados con Nintedanib
P, Á. U. (2022) · Revista chilena de enfermedades respiratorias · doi:10.4067/s0717-73482022000400160
Organizing Pneumonia Versus Usual Interstitial Pneumonia
Mau, B., Johnson, L. N., & Xu, H. (2022) · Pracatical anatomic pathology · doi:10.1007/978-3-031-14402-8_40
Hamouda, S., Ouerfelli, R., Trabelsi, I., et al. (2022) · PubMed
Transplantation pulmonaire pour pneumopathie interstitielle diffuse fibrosante
Mordant, P., Dauriat, G., Brugière, O., Borie, R., Crestani, B., & Reynaud‐Gaubert, M. (2023) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2022.12.012
Idiopathic pulmonary fibrosis - novel approach on future treatment
PACEK, K., Piekarska, M., Pikulicka, A., Jedlina, K., SZULC, I., Kasperski, R., SWACHA, W., & Makowska, K. (2023) · Journal of Education Health and Sport · doi:10.12775/jehs.2023.13.02.039
Bejarano, D. P. (2022) · Memorias del Instituto de Investigaciones en Ciencias de la Salud · doi:10.18004/mem.iics/1812-9528/2022.020.03.148
Pneumologie : ce qui a changé en 2022
Kolb, M., Lechartier, B., Aubert, J., & Daccord, C. (2023) · JMIG · doi:10.53738/revmed.2023.19.809-10.77
Self-citationGui, C., Gong, X., Liu, S., Xie, J., Wang, Y., Guo, W., Liao, W., Song, L., & Zhang, X. (2023) · Research Square · doi:10.21203/rs.3.rs-2530354/v1
Fibroblast growth factors (FGFs) endocrines et fibrogenèse pulmonaire
Ghanem, M., Mailleux, A., & Crestani, B. (2023) · Revue des Maladies Respiratoires · doi:10.1016/j.rmr.2023.01.018
Frail Children with Chronic Lung Disease
Onofri, A., Caggiano, S., Cherchi, C., Testa, M. B. C., & Cutrera, R. (2023) · Springer eBooks · doi:10.1007/978-3-031-24307-3_4
New Guidelines for Idiopathic Pulmonary Fibrosis and Progressive Pulmonary Fibrosis
Yoo, H. (2023) · Korean Journal of Medicine · doi:10.3904/kjm.2023.98.2.64
Behr, J. (2023) · Springer Reference Medizin · doi:10.1007/978-3-642-54676-1_376-2
Interstitial Pneumonia with Autoimmune Features
Sergew, A., Fischer, A., & Brown, K. K. (2023) · Springer eBooks · doi:10.1007/978-3-031-12950-6_15
Self-citationIdiopathic Pulmonary Fibrosis and the Many Faces of UIP
Luppi, F., & Richeldi, L. (2023) · Springer eBooks · doi:10.1007/978-3-031-12950-6_32
Self-citationUnclassifiable Interstitial Lung Disease
Guler, S. A., & Ryerson, C. J. (2023) · Springer eBooks · doi:10.1007/978-3-031-12950-6_38
Huang, Y.-D., & Liu, Z. (2022) · Journal of Student Research · doi:10.47611/jsrhs.v11i2.2633
Idiopathic interstitial pneumonias: Idiopathic pulmonary fibrosis
Higo, H. (2023) · Okayama Igakkai Zasshi (Journal of Okayama Medical Association) · doi:10.4044/joma.135.36
Miyagi, M., & Ebihara, S. (2023) · リハビリテーション医学 : 日本リハビリテーション医学会誌 · doi:10.2490/jjrmc.60.102
An Introduction to Engineering and Modeling the Lung
Tanneberger, A. E., Weiss, D. J., & Magin, C. M. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-26625-6_1 · Cited by 1
Mullor, M. M. G., Arenas-Jiménez, J. J., Vacas, A. U., García‐Manso, I. G., Pérez, J. L. P., Serra, N. S., & Sevila, R. G. (2023) · Radiología · doi:10.1016/j.rx.2023.03.002
Cryobiopsy in Interstitial Lung Disease: Is It Prime Time?
HAMPTON, S. F., Schimmel, M., & Niroula, A. (2023) · Current Pulmonology Reports · doi:10.1007/s13665-023-00310-3
Generoso, L. N., Assis, M. G., de Leucas, P. L. B., Luz, M. B., Moura, M. P., Silva, M. L. M., & Mancuzo, E. V. (2023) · Research Square · doi:10.21203/rs.3.rs-3038904/v1
The Fatigue Severity Scale in Interstitial Lung Disease: An Energizing Endpoint
Wong, A. W., & Johannson, K. A. (2023) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202305-0919ed
Clinical Diagnosis of Pleuroparenchymal Fibroelastosis
Tetikkurt, C. (2022) · Archives of Clinical Trials · doi:10.33425/2768-4598.1026
Zhang, L., Wang, P., Mo, Y., Zhang, Y., Tong, X., Zhang, X., & Li, S. (2023) · Research Square · doi:10.21203/rs.3.rs-3171136/v1
van Zyl-Smit, R. N., Soin, G. K., & Calligaro, G. (2023) · African Journal of Thoracic and Critical Care Medicine · doi:10.7196/ajtccm.2023.v29i2.803
Bridging the gap: Communicating the results of ventilation/perfusion scans to clinicians
Moolla, M. S., Doruyter, A., & Allwood, B. (2023) · African Journal of Thoracic and Critical Care Medicine · doi:10.7196/ajtccm.2023.v29i2.1231
Pneumopathies interstitielles diffuses fibrosantes : perspectives diagnostiques et thérapeutiques
Bouvry, D. (2023) · Revue des Maladies Respiratoires Actualités · doi:10.1016/s1877-1203(23)00075-7
Lee, Y. H., & Song, G. G. (2023) · Iranian Journal of Public Health · doi:10.18502/ijph.v52i9.13561
Recipient Selection and the Lung Transplant Window for Adult and Pediatric Patients
Neujahr, D. C., & Hunt, W. R. (2023) · Wiley eBooks · doi:10.1002/9781119633884.ch74
Gries, C. (2023) · Wiley eBooks · doi:10.1002/9781119633884.ch75
Fujiwara, K., Tsuji, A. B., Sudo, H., Sugyo, A., Hamakubo, T., & Higashi, T. (2023) · Nuclear Medicine Communications · doi:10.1097/mnm.0000000000001775
Veit, T., & Behr, J. (2023) · Zeitschrift für Pneumologie · doi:10.1007/s10405-023-00525-w
Zlatanova, T., & Arabadjiev, J. I. (2023) · Pharmacia · doi:10.3897/pharmacia.70.e111820
What Special Considerations Are Needed for Patients With Advanced Lung Disease?
Wagner, C. J., & Iyer, A. S. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-84702-5.00052-x
Asl, M. S., Motakef, Z., Behgam, N., Attaran, S., & Mirsadraee, M. (2023) · PubMed Central
Tanaka, S., Tsuji, T., Jinno, K., et al. (2023) · Cureus · doi:10.7759/cureus.49528
“In addition, the proportion of patients who experienced AE was also significantly reduced in the nintedanib group [19].”
BackgroundFeatures of the course of idiopathic fibrosing alveolitis
Gulyabin, K. R. (2023) · Spravočnik vrača obŝej praktiki (Journal of Family Medicine) · doi:10.33920/med-10-2311-07
Xu, Z., Zeng, A., Yin, Y., Chen, K., Wang, C., Fang, X., Abuduwayiti, A., Wang, J., Jiang, G., & Dai, J. (2023) · Research Square · doi:10.21203/rs.3.rs-3724996/v1
Case report: anti-synthase syndrome associated with SARS-Cov-2 infectionPreprint
Chen, X., Chen, J., Zhi, L.-J., et al. (2023) · Research Square · doi:10.21203/rs.3.rs-3720886/v1
Macrolides and Interstitial Lung Diseases
Hara, Y., & Kaneko, T. (2024) · Progress in inflammation research · doi:10.1007/978-3-031-42859-3_8
Molecular mechanisms of idiopathic pulmonary fibrosis: Emerging therapeutic approaches
Araújo, V. S., Siqueira, A. M. D. P., Teixeira, C. S., Serafim, E. C. G., Gregório, É. M. S., de Mello, I. G. K. A., Mello, I. G. K. A. D., Laudelino, J. S., Costa, S. M., & Mororó, S. H. V. (2024) · Seven Editora eBooks · doi:10.56238/sevened2023.007-033
Tanaka, K., Shimoda, M., Sugizaki, T., et al. (2024) · doi:10.22541/au.170667892.29390313/v1
Idiopathic Pulmonary Fibrosis Comorbid With Mediastinal Small Cell Carcinoma: A Clinical Dilemma
Shakir, M. H., Basit, S. A., Ray, B. K., et al. (2024) · Cureus · doi:10.7759/cureus.53578
Diagnostic and prognostic value of serum amiloid a in patients with idiopatic pulmonary fibrosis
Yalçın, S., Yüceege, M., & Kurt, B. (2024) · Journal of Pulmonology and Intensive Care · doi:10.51271/jopic-0024
Nintedanib zur Therapie der radiogenen Pneumonitis
Dejonckheere, C. S., Höller, U., & Käsmann, L. (2024) · Strahlentherapie und Onkologie · doi:10.1007/s00066-024-02216-8
Capaccione, K. M., Ma, H., Luk, L., & Salvatore, M. M. (2024) · Imaging · doi:10.1556/1647.2024.00190
La fibrosis pulmonar vista desde sus primeros casos publicados en México
Buendía-Roldán, I. (2024) · NCT Neumología y Cirugía de Tórax · doi:10.35366/114818
Lipid-lowering drug targets and lung related diseases: a Mendelian randomization study
Yu, H., Zhang, X., Wen, B., Hu, S., & Ni, B. (2024) · All Life · doi:10.1080/26895293.2024.2329440
Biomarkers and phenotype concepts in sarcoidosis care
Schimmelpennink, M. C. (2024) · Utrecht University Repository (Utrecht University) · doi:10.33540/2085
Adoptive transfer of CD49a + Tissue resident memory cells reverses pulmonary fibrosis in micePreprint
Collins, S. L., Chan‐Li, Y., Shenderov, K., Gillich, A., Nelson, A. M., Loube, J., Mitzner, W., Powell, J. D., & Horton, M. R. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.13.584814
Radioproteomics stratifies molecular response to antifibrotic treatment in pulmonary fibrosisPreprint
Lauer, D., Magnin, C., Kolly, L. R., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.03.27.586923
Yamazaki, R., Nishiyama, O., Yosikawa, K., et al. (2024) · Respiratory Investigation · doi:10.1016/j.resinv.2024.03.008
Progress in Drug Therapy for Idiopathic Pulmonary Fibrosis
洪, 阳. (2024) · Advances in Clinical Medicine · doi:10.12677/acm.2024.1441004
Ebrahimpour, A., Wang, M., Li, L., Jegga, A. G., Bonnen, M., Eissa, N. T., Raghu, G., Jyothula, S., Kheradmand, F., Hanania, N. A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14623160
Self-citationEbrahimpour, A., Wang, M., Li, L., Jegga, A. G., Bonnen, M., Eissa, N. T., Raghu, G., Jyothula, S., Kheradmand, F., Hanania, N. A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14623163
Self-citationAdditional file 1 of PTK2-associated gene signature could predict the prognosis of IPF
Feng, A., Caro, Y. M., Gardner, C., Grischo, G., Liang, Y., Wickremasinghe, P. D., Polmann, M. B., Kala, M., Marlowe, T. A., Black, S. M., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24751209
Ebrahimpour, A., Wang, M., Li, L., Jegga, A. G., Bonnen, M., Eissa, N. T., Raghu, G., Jyothula, S., Kheradmand, F., Hanania, N. A., et al. (2021) · Figshare · doi:10.6084/m9.figshare.14623166
Self-citationYang, F., Du, W., Tang, Z., Wei, Y., & Dong, J. (2023) · Figshare · doi:10.6084/m9.figshare.22617857
Luo, H., Wang, S., Yang, G., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4789972
Lin, M., Wang, J., Wei, J., Yao, Y., Tang, C., Jin, W., Yuan, W., & Lv, Y. (2024) · European Journal of Inflammation · doi:10.1177/1721727x241247761
Drug Development and Regulatory Considerations for Systemic Sclerosis Therapies
Wung, P. K., & Guettier, J. (2024) · Springer eBooks · doi:10.1007/978-3-031-40658-4_49
Mai, T. H., Yadav, R., Arjomandi, A., Jung, C. J., Meier, M., Donaldson, F., Zhao, R. Z., Ding, H., Hsu, J. C., Kamath, N., et al. (2024) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.1403
Treatment of Interstitial Lung Disease in Systemic Sclerosis
Elhaï, M., Crestani, B., Muraru-Carbrune, M.-S., & Allanore, Y. (2024) · Springer eBooks · doi:10.1007/978-3-031-40658-4_26
Progressive Interstitial Lung Disease Non-Responsive to Immunosuppressive Therapy
Silver, K., Highland, K. B., & Silver, R. M. (2024) · Springer eBooks · doi:10.1007/978-3-031-40658-4_55
Idiopathische Lungenfibrose: Evidenz versus Realität
Storre, M.-L. (2024) · Pneumo News · doi:10.1007/s15033-024-4001-2
Pugashetti, J. V., & Wolters, P. J. (2024) · CHEST Journal · doi:10.1016/j.chest.2023.12.023
Review of indole, A versatile pharmacophoric moiety
Gaikwad, V. (2024) · Current Trends in Pharmacy and Pharmaceutical Chemistry · doi:10.18231/j.ctppc.2024.011
Qiu, W., Wang, Q., Zhang, Y., Cao, X., Zhao, L., Cao, L., Sun, Y., Yang, F. L., Guo, Y., Sui, Y., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4823578
Ray, R. S., Bhowmik, R., Shyamal, S. S., Manaithiya, A., Gong, W., Parkkila, S., & Aspatwar, A. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.26.595932
Teodorescu-Drăghicescu, Ș., & Strambu, I. R. (2023) · Pneumologia · doi:10.2478/pneum-2024-0010
Nintedanib: beneficial agent in post-COVID-19 Pulmonary Fibrosis
Țău, V., Antal, A. Z., Antohi, P. V., Stoian, I. A., Pintilie, A.-L., Trofor, A. C., & Crișan-Dabija, R. A. (2023) · Pneumologia · doi:10.2478/pneum-2024-0014
Vancheri, A., Ravaglia, C., Piciucchi, S., Sorino, C., & Poletti, V. E. (2024) · Elsevier eBooks · doi:10.1016/b978-0-323-93522-7.00011-2
A Commentary on the Role of Pulmonary Function Parameters in Idiopathic Pulmonary Fibrosis Follow‐Up
Degirmenci, G., & Satıcı, C. (2024) · The Clinical Respiratory Journal · doi:10.1111/crj.13797
Outcome after nintedanib therapy for fibrosing interstitial lung disease in patients without dyspneaPreprint
Okamoto, M., Yanagihara, T., Fujimoto, K., et al. (2024) · Research Square · doi:10.21203/rs.3.rs-4513070/v1
Clinically Relevant Biomarkers in Connective Tissue Disease-Associated Interstitial Lung Disease
Pugashetti, J. V., Khanna, D., Kazerooni, E. A., & Oldham, J. M. (2024) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2024.03.007
Cheng, W.-C., Chen, P. Y., Zhang, X., Chang, Y., Tan, K., & Lin, T. C. C. (2024) · Immunopharmacology and Immunotoxicology · doi:10.1080/08923973.2024.2371150 · Cited by 1
Han, X., Wang, Q., Liu, S., et al. (2024) · SSRN Electronic Journal · doi:10.2139/ssrn.4884695
Ono, M., Kobayashi, S., Hanagama, M., Ishida, M., Sato, H., Okutomo, K., Shirai, Y., Takahashi, K., Yamada, M., Fujino, N., et al. (2024) · Medicine · doi:10.1097/md.0000000000038920 · Cited by 1
Matsui, Y., Abe, M., Uematsu, Y., Onozato, Y., Yamamoto, T., & Iwata, T. (2024) · The Journal of the Japanese Association for Chest Surgery · doi:10.2995/jacsurg.38.446
Shah, N. (2024) · Diseases · doi:10.3390/diseases12070155
“While nintedanib and pirfenidone are effective in slowing lung function decline, they show limited efficacy in alleviating symptoms or improving HRQOL in IPF patients [18,19].”
Background
Metadata
- Authors
- Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., Kim, D. S., Kolb, M., Nicholson, A. G., Noble, P. W., Selman, M., Taniguchi, H., Brun, M., Le Maulf, F., Girard, M., Stowasser, S., Schlenker-Herceg, R., Disse, B., & Collard, H. R.
- Affiliations
- NIHR Southampton Respiratory Biomedical Research Unit (GB)
- University of Washington (US)
- Nippon Medical School (JP)
- Ruhrlandklinik (DE)
- Université de Lyon (FR)
- Michigan Medicine (US)
- Royal Brompton & Harefield NHS Foundation Trust (GB)
- NHO Kinki Chuo Chest Medical Center (JP)
- Asan Medical Center (KR)
- McMaster University (CA)
- Cedars-Sinai Medical Center (US)
- Instituto Nacional de Enfermedades Respiratorias (MX)
- Tosei General Hospital (JP)
- Boehringer Ingelheim (Germany) (DE)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2014-05-29
- Volume
- 370
- Issue
- 22
- Pages
- 2071-2082
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138871107
- Cited by
- 4,654
- References
- 21
- Citations by year
- 2026: 338 · 2025: 372 · 2024: 479 · 2023: 412 · 2022: 429 · 2021: 501 · 2020: 423 · 2019: 350 · 2018: 345 · 2017: 328 · 2016: 293 · 2015: 292 · 2014: 74
- FWCI
- 263.74
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Use Siena air (University of Siena) (submittedVersion, cc-by-nc-nd)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Digital Access to Libraries (submittedVersion)
- ePrints Soton (University of Southampton) (submittedVersion)
- IRIS UNIMORE (University of Modena and Reggio Emilia) (submittedVersion, cc-by)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Padua Research Archive (University of Padova) (submittedVersion)
- Funders
- Amgen
- Pfizer
- GlaxoSmithKline
- Sanofi
- Gilead Sciences
- Biogen
- Celgene
- FibroGen
- Ikaria
- University Hospital Southampton NHS Foundation Trust
- Massachusetts Medical Society
- Royal Brompton and Harefield NHS Foundation Trust
- Galecto
- Veracyte
- National Institute for Health and Care Research (NF-SI-0512-10157)
- Imperial College London
- Shionogi
- Genentech
- Japan Society for the Promotion of Science (24591149)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- nintedanib, idiopathic pulmonary fibrosis, tyrosine kinase inhibitors, forced vital capacity decline, acute exacerbation, St George's Respiratory Questionnaire, drug safety, INPULSIS trials, lung function preservation, adverse events, diarrhea, liver enzymes, proteinuria, thrombocytopenia, neutropenia, antifibrotic therapy
- MeSH terms
- Aged, Double-Blind Method, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Protein-Tyrosine Kinases, Quality of Life, Vital Capacity, Treatment Outcome, Disease Progression, Protein Kinase Inhibitors, Idiopathic Pulmonary Fibrosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.